SOLV Solventum Corporation
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Solventum (NYSE: SOLV)
›
Solventum (NYSE: SOLV) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 20,584 employees.
The shares were at 84.50 USD on 20 November 2026, up 10.9% over 52 weeks. Its 52-week range is 62.38 USD to 94.16 USD: the price is 10.3% below the high and 35.5% above the low.
At a market capitalisation of 14.36B USD, it trades at 94.9 times trailing earnings and 11.2 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 47.2, a premium of 101% for SOLV.
Solventum reports return on equity of 30.8%, an operating margin of 5.9% and revenue down 7.0% year over year.
Its debt exceeds its cash by 4.84B USD, a debt-to-equity ratio of 1.00. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 98.38 USD is 16.4% above the current price. The next earnings report is expected on 25 February 2027.